Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study June 2025 Congress News Read more
2022 January Pharma News Acalabrutinib for previously treated CLL: as effective but better tolerated than ibrutinib Read more
2021 October Science The immune evasion strategy of primary testicular and central nervous system lymphomas Read more
2021 October Prevention Novel triplet treatment reduces the risk of progression to symptomatic multiple myeloma Read more
2021 October Clinical practice Treatment with hydroxyurea may lead to reverse cardiac remodelling in young adults with SCA Read more
Top
